English

REPROS THERAPEUTICS INC.

EDGAR

RPRX Filing (4) · filed 2018-01-31

126 filing records in this dataset, filed from 1996-05-15 to 2018-01-31. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

304 thousand USD

2017 Q3 · USD

Exact inputs and evidence

Revenue: 304000 USD Source

Net margin

-531.25%

2017 Q3 · %

Exact inputs and evidence

Net Income: -1615000 USD Source
Revenue: 304000 USD Source

Operating cash flow

-1.95 million USD

2017 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -8549000 USD Source
Operating Cash Flow: -6597000 USD Source

Free cash flow

-1.95 million USD

2017 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -8549000 USD Source
Operating Cash Flow: -6597000 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 1.81 million USD 2017-09-30 Source
Exact value

1813000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 39.5 million shares 2017-09-30 Source
Exact value

39489807 shares

Reported share-count change

57.16% · 14.4 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

25126784 shares · 2016-09-30· Source
39489807 shares · 2017-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

323 thousand USD

2016-10-01 – 2017-09-30

Exact inputs and evidence

Revenue: 5000 USD · 2016-10-01 – 2016-12-31 Source
Revenue: 7000 USD · 2017-01-01 – 2017-03-31 Source
Revenue: 7000 USD · 2017-04-01 – 2017-06-30 Source
Revenue: 304000 USD · 2017-07-01 – 2017-09-30 Source

Net income

-13.7 million USD

2016-10-01 – 2017-09-30

Exact inputs and evidence

Net income: -3980000 USD · 2016-10-01 – 2016-12-31 Source
Net income: -5910000 USD · 2017-01-01 – 2017-03-31 Source
Net income: -2199000 USD · 2017-04-01 – 2017-06-30 Source
Net income: -1615000 USD · 2017-07-01 – 2017-09-30 Source

Operating cash flow

-11.6 million USD

2016-10-01 – 2017-09-30

Exact inputs and evidence

Operating cash flow: -15581000 USD · 2016-01-01 – 2016-12-31 Source
Operating cash flow: -12482000 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: -4618000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -6597000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -4618000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: -8549000 USD · 2017-01-01 – 2017-09-30 Source
Operating cash flow: -6597000 USD · 2017-01-01 – 2017-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2018-01-31.

Financial data available through: 2016-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2016-12-31
operating income: No compatible figures in this window
Net income: 11 of 11 periods available· newest 2016-12-31
Operating cash flow: 11 of 11 periods available· newest 2016-12-31
Capital expenditure: 11 of 11 periods available· newest 2016-12-31
Total assets: 11 of 11 periods available· newest 2016-12-31
Total liabilities: 1 of 11 periods available· newest 2016-12-31
Current assets: 11 of 11 periods available· newest 2016-12-31
Current liabilities: 11 of 11 periods available· newest 2016-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2016-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2016-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+327.3%

Prior period

USD 11,000

2015-01-01 – 2015-12-31
Current period

USD 47,000

2016-01-01 – 2016-12-31

Exact inputs and evidence

47000 − 11000 = 36000 USD

11000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
47000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · REPROS THERAPEUTICS INC. · 2016-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Year-over-year change in Revenue: 36000 USD Concept: fundies:Revenue Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 47000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#67426 Filing: 000114420417017919 Input fundies:Revenue: 11000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#67300 Filing: 000114420417017919
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 11.92 million

Prior period

−USD 29.19 million

2015-01-01 – 2015-12-31
Current period

−USD 17.27 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

-17273000 − -29192000 = 11919000 USD

-29192000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
-17273000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · REPROS THERAPEUTICS INC. · 2016-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Year-over-year change in Net income: 11919000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -17273000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#68672 Filing: 000114420417017919 Input fundies:NetIncome: -29192000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#68532 Filing: 000114420417017919
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 9.75 million

Prior period

−USD 25.33 million

2015-01-01 – 2015-12-31
Current period

−USD 15.58 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

-15581000 − -25329000 = 9748000 USD

-25329000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
-15581000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · REPROS THERAPEUTICS INC. · 2016-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Year-over-year change in Operating cash flow: 9748000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -15581000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73229 Filing: 000114420417017919 Input fundies:OperatingCashFlow: -25329000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73031 Filing: 000114420417017919
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
USD 0

Prior period

USD 0

2015-01-01 – 2015-12-31
Current period

USD 0

2016-01-01 – 2016-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
0 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · REPROS THERAPEUTICS INC. · 2016-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Year-over-year change in Capital expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73617 Filing: 000114420417017919 Input fundies:CapitalExpenditure: 0 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73427 Filing: 000114420417017919
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2016 2016-01-01 – 2016-12-31

Revenue USD 47,000 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income −USD 17.27 million −36,751% of revenue

Cash

Operating cash flow −USD 15.58 million −33,151% of revenue
Capital expenditure USD 0 0% of revenue
Free cash flow Derived −USD 15.58 million −33,151% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2007 Not shown: operating income or net income is not reported.
2008 Not shown: operating income or net income is not reported.
2009 Not shown: operating income or net income is not reported.
2010 Not shown: operating income or net income is not reported.
2011 Not shown: operating income or net income is not reported.
2012 Not shown: operating income or net income is not reported.
2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2007 2007-01-01 – 2007-12-31	1508000	Unavailable	Unavailable	Unavailable	-13700000	-13563000 Derived	Source 2007-01-01 – 2007-12-31: 1508000 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: -13700000 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: -13557000 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 6000 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	433000	Unavailable	Unavailable	Unavailable	-25202000	-21749000 Derived	Source 2008-01-01 – 2008-12-31: 433000 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -25202000 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: -21745000 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 4000 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	551000	Unavailable	Unavailable	Unavailable	-27234000	-22081000 Derived	Source 2009-01-01 – 2009-12-31: 551000 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: -27234000 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: -22081000 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 0 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	421000	Unavailable	Unavailable	Unavailable	-4768000	-4959000 Derived	Source 2010-01-01 – 2010-12-31: 421000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -4768000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -4952000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 7000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	2000	Unavailable	Unavailable	Unavailable	-12491000	-9779000 Derived	Source 2011-01-01 – 2011-12-31: 2000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -12491000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -9764000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 15000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	3000	Unavailable	Unavailable	Unavailable	-18944000	-14103000 Derived	Source 2012-01-01 – 2012-12-31: 3000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -18944000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -14073000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 30000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	9000	Unavailable	Unavailable	Unavailable	-28466000	-25359000 Derived	Source 2013-01-01 – 2013-12-31: 9000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -28466000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -25296000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 63000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	9000	Unavailable	Unavailable	Unavailable	-32535000	-29334000 Derived	Source 2014-01-01 – 2014-12-31: 9000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -32535000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -29334000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 0 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	11000	Unavailable	Unavailable	Unavailable	-29192000	-25329000 Derived	Source 2015-01-01 – 2015-12-31: 11000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -29192000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -25329000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 0 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	47000	Unavailable	Unavailable	Unavailable	-17273000	-15581000 Derived	Source 2016-01-01 – 2016-12-31: 47000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -17273000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -15581000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 47K 2016

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Revenue	1508000	Revenue: 1508000 Open source
20082008-12-31	Revenue	433000	Revenue: 433000 Open source
20092009-12-31	Revenue	551000	Revenue: 551000 Open source
20102010-12-31	Revenue	421000	Revenue: 421000 Open source
20112011-12-31	Revenue	2000	Revenue: 2000 Open source
20122012-12-31	Revenue	3000	Revenue: 3000 Open source
20132013-12-31	Revenue	9000	Revenue: 9000 Open source
20142014-12-31	Revenue	9000	Revenue: 9000 Open source
20152015-12-31	Revenue	11000	Revenue: 11000 Open source
20162016-12-31	Revenue	47000	Revenue: 47000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

327.3% 2016

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Year over year	153%	Revenue: 1508000 Open source Revenue: 596000 Open source
20082008-12-31	Year over year	-71.3%	Revenue: 433000 Open source Revenue: 1508000 Open source
20092009-12-31	Year over year	27.3%	Revenue: 551000 Open source Revenue: 433000 Open source
20102010-12-31	Year over year	-23.6%	Revenue: 421000 Open source Revenue: 551000 Open source
20112011-12-31	Year over year	-99.5%	Revenue: 2000 Open source Revenue: 421000 Open source
20122012-12-31	Year over year	50%	Revenue: 3000 Open source Revenue: 2000 Open source
20132013-12-31	Year over year	200%	Revenue: 9000 Open source Revenue: 3000 Open source
20142014-12-31	Year over year	0%	Revenue: 9000 Open source Revenue: 9000 Open source
20152015-12-31	Year over year	22.2%	Revenue: 11000 Open source Revenue: 9000 Open source
20162016-12-31	Year over year	327.3%	Revenue: 47000 Open source Revenue: 11000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Net margin -36,751.1% 2016

Free cash flow margin -33,151.1% 2016

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2007-12-31	Operating margin	Not reported	Revenue: 1508000 Open source
2008-12-31	Operating margin	Not reported	Revenue: 433000 Open source
2009-12-31	Operating margin	Not reported	Revenue: 551000 Open source
2010-12-31	Operating margin	Not reported	Revenue: 421000 Open source
2011-12-31	Operating margin	Not reported	Revenue: 2000 Open source
2012-12-31	Operating margin	Not reported	Revenue: 3000 Open source
2013-12-31	Operating margin	Not reported	Revenue: 9000 Open source
2014-12-31	Operating margin	Not reported	Revenue: 9000 Open source
2015-12-31	Operating margin	Not reported	Revenue: 11000 Open source
2016-12-31	Operating margin	Not reported	Revenue: 47000 Open source
20072007-12-31	Net margin	-908.5%	Net Income: -13700000 Open source Revenue: 1508000 Open source
20082008-12-31	Net margin	-5,820.3%	Net Income: -25202000 Open source Revenue: 433000 Open source
20092009-12-31	Net margin	-4,942.6%	Net Income: -27234000 Open source Revenue: 551000 Open source
20102010-12-31	Net margin	-1,132.5%	Net Income: -4768000 Open source Revenue: 421000 Open source
20112011-12-31	Net margin	-624,550%	Net Income: -12491000 Open source Revenue: 2000 Open source
20122012-12-31	Net margin	-631,466.7%	Net Income: -18944000 Open source Revenue: 3000 Open source
20132013-12-31	Net margin	-316,288.9%	Net Income: -28466000 Open source Revenue: 9000 Open source
20142014-12-31	Net margin	-361,500%	Net Income: -32535000 Open source Revenue: 9000 Open source
20152015-12-31	Net margin	-265,381.8%	Net Income: -29192000 Open source Revenue: 11000 Open source
20162016-12-31	Net margin	-36,751.1%	Net Income: -17273000 Open source Revenue: 47000 Open source
20072007-12-31	Free cash flow margin	-899.4%	Revenue: 1508000 Open source Operating Cash Flow: -13557000 Open source Capital Expenditure: 6000 Open source
20082008-12-31	Free cash flow margin	-5,022.9%	Revenue: 433000 Open source Operating Cash Flow: -21745000 Open source Capital Expenditure: 4000 Open source
20092009-12-31	Free cash flow margin	-4,007.4%	Revenue: 551000 Open source Operating Cash Flow: -22081000 Open source Capital Expenditure: 0 Open source
20102010-12-31	Free cash flow margin	-1,177.9%	Revenue: 421000 Open source Operating Cash Flow: -4952000 Open source Capital Expenditure: 7000 Open source
20112011-12-31	Free cash flow margin	-488,950%	Revenue: 2000 Open source Operating Cash Flow: -9764000 Open source Capital Expenditure: 15000 Open source
20122012-12-31	Free cash flow margin	-470,100%	Revenue: 3000 Open source Operating Cash Flow: -14073000 Open source Capital Expenditure: 30000 Open source
20132013-12-31	Free cash flow margin	-281,766.7%	Revenue: 9000 Open source Operating Cash Flow: -25296000 Open source Capital Expenditure: 63000 Open source
20142014-12-31	Free cash flow margin	-325,933.3%	Revenue: 9000 Open source Operating Cash Flow: -29334000 Open source Capital Expenditure: 0 Open source
20152015-12-31	Free cash flow margin	-230,263.6%	Revenue: 11000 Open source Operating Cash Flow: -25329000 Open source Capital Expenditure: 0 Open source
20162016-12-31	Free cash flow margin	-33,151.1%	Revenue: 47000 Open source Operating Cash Flow: -15581000 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -15.6M 2016

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Operating cash flow	-13557000	Operating Cash Flow: -13557000 Open source
20082008-12-31	Operating cash flow	-21745000	Operating Cash Flow: -21745000 Open source
20092009-12-31	Operating cash flow	-22081000	Operating Cash Flow: -22081000 Open source
20102010-12-31	Operating cash flow	-4952000	Operating Cash Flow: -4952000 Open source
20112011-12-31	Operating cash flow	-9764000	Operating Cash Flow: -9764000 Open source
20122012-12-31	Operating cash flow	-14073000	Operating Cash Flow: -14073000 Open source
20132013-12-31	Operating cash flow	-25296000	Operating Cash Flow: -25296000 Open source
20142014-12-31	Operating cash flow	-29334000	Operating Cash Flow: -29334000 Open source
20152015-12-31	Operating cash flow	-25329000	Operating Cash Flow: -25329000 Open source
20162016-12-31	Operating cash flow	-15581000	Operating Cash Flow: -15581000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -15.6M 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Free cash flow	-13563000	Operating Cash Flow: -13557000 Open source Capital Expenditure: 6000 Open source
20082008-12-31	Free cash flow	-21749000	Operating Cash Flow: -21745000 Open source Capital Expenditure: 4000 Open source
20092009-12-31	Free cash flow	-22081000	Operating Cash Flow: -22081000 Open source Capital Expenditure: 0 Open source
20102010-12-31	Free cash flow	-4959000	Operating Cash Flow: -4952000 Open source Capital Expenditure: 7000 Open source
20112011-12-31	Free cash flow	-9779000	Operating Cash Flow: -9764000 Open source Capital Expenditure: 15000 Open source
20122012-12-31	Free cash flow	-14103000	Operating Cash Flow: -14073000 Open source Capital Expenditure: 30000 Open source
20132013-12-31	Free cash flow	-25359000	Operating Cash Flow: -25296000 Open source Capital Expenditure: 63000 Open source
20142014-12-31	Free cash flow	-29334000	Operating Cash Flow: -29334000 Open source Capital Expenditure: 0 Open source
20152015-12-31	Free cash flow	-25329000	Operating Cash Flow: -25329000 Open source Capital Expenditure: 0 Open source
20162016-12-31	Free cash flow	-15581000	Operating Cash Flow: -15581000 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

30.4% 2016

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2007-12-31	Liabilities / assets	Not reported	Total Assets: 27599000 Open source
2008-12-31	Liabilities / assets	Not reported	Total Assets: 22603000 Open source
2009-12-31	Liabilities / assets	Not reported	Total Assets: 2960000 Open source
2010-12-31	Liabilities / assets	Not reported	Total Assets: 4465000 Open source
2011-12-31	Liabilities / assets	Not reported	Total Assets: 6064000 Open source
2012-12-31	Liabilities / assets	Not reported	Total Assets: 26832000 Open source
2013-12-31	Liabilities / assets	Not reported	Total Assets: 76071000 Open source
2014-12-31	Liabilities / assets	Not reported	Total Assets: 46941000 Open source
2015-12-31	Liabilities / assets	Not reported	Total Assets: 21485000 Open source
20162016-12-31	Liabilities / assets	30.4%	Total Liabilities: 2659000 Open source Total Assets: 8757000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.29× 2016

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Current assets / current liabilities	7.45×	Current Assets: 26382000 Open source Current Liabilities: 3539000 Open source
20082008-12-31	Current assets / current liabilities	2.98×	Current Assets: 20862000 Open source Current Liabilities: 6989000 Open source
20092009-12-31	Current assets / current liabilities	0.86×	Current Assets: 2063000 Open source Current Liabilities: 2398000 Open source
20102010-12-31	Current assets / current liabilities	2.53×	Current Assets: 3285000 Open source Current Liabilities: 1298000 Open source
20112011-12-31	Current assets / current liabilities	3.34×	Current Assets: 4664000 Open source Current Liabilities: 1398000 Open source
20122012-12-31	Current assets / current liabilities	6.48×	Current Assets: 24618000 Open source Current Liabilities: 3798000 Open source
20132013-12-31	Current assets / current liabilities	21.4×	Current Assets: 75996000 Open source Current Liabilities: 3552000 Open source
20142014-12-31	Current assets / current liabilities	16.04×	Current Assets: 46909000 Open source Current Liabilities: 2924000 Open source
20152015-12-31	Current assets / current liabilities	7.36×	Current Assets: 21477000 Open source Current Liabilities: 2918000 Open source
20162016-12-31	Current assets / current liabilities	3.29×	Current Assets: 8754000 Open source Current Liabilities: 2659000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2007 2007-01-01 – 2007-12-31	−USD 13.7 million Exact value Exact value: -13700000 USD 2007-01-01 – 2007-12-31: -13700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2007-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -13700000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13700000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#420338 Filing: 000114420414015649 The citation records this snapshot. The page link may show a newer release later.	−USD 13.56 million Exact value Exact value: -13557000 USD 2007-01-01 – 2007-12-31: -13557000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2007-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -13557000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13557000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-10-013427.txt#20492 The citation records this snapshot. The page link may show a newer release later.	USD 6,000 Exact value Exact value: 6000 USD 2007-01-01 – 2007-12-31: 6000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2007-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 6000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-10-013427.txt#20578 The citation records this snapshot. The page link may show a newer release later.	−USD 13.56 million Calculation and evidence -13557000 − 6000 USD Exact free cash flow: -13563000 USD 2007-01-01 – 2007-12-31: -13557000 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 6000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2007-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -13563000 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13557000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-10-013427.txt#20492 Input fundies:CapitalExpenditure: 6000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-10-013427.txt#20578 The citation records this snapshot. The page link may show a newer release later.
2008 2008-01-01 – 2008-12-31	−USD 25.2 million Exact value Exact value: -25202000 USD 2008-01-01 – 2008-12-31: -25202000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2008-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -25202000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25202000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#420728 Filing: 000114420414015649 The citation records this snapshot. The page link may show a newer release later.	−USD 21.75 million Exact value Exact value: -21745000 USD 2008-01-01 – 2008-12-31: -21745000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2008-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -21745000 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21745000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-11-017629.txt#16779 The citation records this snapshot. The page link may show a newer release later.	USD 4,000 Exact value Exact value: 4000 USD 2008-01-01 – 2008-12-31: 4000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2008-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 4000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-11-017629.txt#16857 The citation records this snapshot. The page link may show a newer release later.	−USD 21.75 million Calculation and evidence -21745000 − 4000 USD Exact free cash flow: -21749000 USD 2008-01-01 – 2008-12-31: -21745000 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 4000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2008-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -21749000 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21745000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-11-017629.txt#16779 Input fundies:CapitalExpenditure: 4000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-11-017629.txt#16857 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	−USD 27.23 million Exact value Exact value: -27234000 USD 2009-01-01 – 2009-12-31: -27234000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2009-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -27234000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27234000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#421118 Filing: 000114420414015649 The citation records this snapshot. The page link may show a newer release later.	−USD 22.08 million Exact value Exact value: -22081000 USD 2009-01-01 – 2009-12-31: -22081000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2009-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -22081000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22081000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420412017347/rprx-20111231.xml#101964 Filing: 000114420412017347 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2009-01-01 – 2009-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2009-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-11-017629.txt#16857 The citation records this snapshot. The page link may show a newer release later.	−USD 22.08 million Calculation and evidence -22081000 − 0 USD Exact free cash flow: -22081000 USD 2009-01-01 – 2009-12-31: -22081000 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2009-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -22081000 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22081000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420412017347/rprx-20111231.xml#101964 Filing: 000114420412017347 Input fundies:CapitalExpenditure: 0 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/0001144204-11-017629.txt#16857 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	−USD 4.77 million Exact value Exact value: -4768000 USD 2010-01-01 – 2010-12-31: -4768000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2010-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -4768000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4768000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#421508 Filing: 000114420414015649 The citation records this snapshot. The page link may show a newer release later.	−USD 4.95 million Exact value Exact value: -4952000 USD 2010-01-01 – 2010-12-31: -4952000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2010-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -4952000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4952000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420413015663/rprx-20121231.xml#415012 Filing: 000114420413015663 The citation records this snapshot. The page link may show a newer release later.	USD 7,000 Exact value Exact value: 7000 USD 2010-01-01 – 2010-12-31: 7000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2010-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420413015663/rprx-20121231.xml#416390 Filing: 000114420413015663 The citation records this snapshot. The page link may show a newer release later.	−USD 4.96 million Calculation and evidence -4952000 − 7000 USD Exact free cash flow: -4959000 USD 2010-01-01 – 2010-12-31: -4952000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 7000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2010-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -4959000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4952000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420413015663/rprx-20121231.xml#415012 Filing: 000114420413015663 Input fundies:CapitalExpenditure: 7000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420413015663/rprx-20121231.xml#416390 Filing: 000114420413015663 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	−USD 12.49 million Exact value Exact value: -12491000 USD 2011-01-01 – 2011-12-31: -12491000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2011-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -12491000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12491000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#320518 Filing: 000114420414015649 The citation records this snapshot. The page link may show a newer release later.	−USD 9.76 million Exact value Exact value: -9764000 USD 2011-01-01 – 2011-12-31: -9764000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2011-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -9764000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9764000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#484127 Filing: 000114420414015649 The citation records this snapshot. The page link may show a newer release later.	USD 15,000 Exact value Exact value: 15000 USD 2011-01-01 – 2011-12-31: 15000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2011-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 15000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#485652 Filing: 000114420414015649 The citation records this snapshot. The page link may show a newer release later.	−USD 9.78 million Calculation and evidence -9764000 − 15000 USD Exact free cash flow: -9779000 USD 2011-01-01 – 2011-12-31: -9764000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 15000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2011-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -9779000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9764000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#484127 Filing: 000114420414015649 Input fundies:CapitalExpenditure: 15000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420414015649/rprx-20131231.xml#485652 Filing: 000114420414015649 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	−USD 18.94 million Exact value Exact value: -18944000 USD 2012-01-01 – 2012-12-31: -18944000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2012-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -18944000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18944000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420415016200/rprx-20141231.xml#114827 Filing: 000114420415016200 The citation records this snapshot. The page link may show a newer release later.	−USD 14.07 million Exact value Exact value: -14073000 USD 2012-01-01 – 2012-12-31: -14073000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2012-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -14073000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14073000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420415016200/rprx-20141231.xml#159555 Filing: 000114420415016200 The citation records this snapshot. The page link may show a newer release later.	USD 30,000 Exact value Exact value: 30000 USD 2012-01-01 – 2012-12-31: 30000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2012-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 30000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 30000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420415016200/rprx-20141231.xml#160152 Filing: 000114420415016200 The citation records this snapshot. The page link may show a newer release later.	−USD 14.1 million Calculation and evidence -14073000 − 30000 USD Exact free cash flow: -14103000 USD 2012-01-01 – 2012-12-31: -14073000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 30000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2012-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -14103000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14073000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420415016200/rprx-20141231.xml#159555 Filing: 000114420415016200 Input fundies:CapitalExpenditure: 30000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420415016200/rprx-20141231.xml#160152 Filing: 000114420415016200 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 28.47 million Exact value Exact value: -28466000 USD 2013-01-01 – 2013-12-31: -28466000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2013-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -28466000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28466000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420416087730/rprx-20151231.xml#67443 Filing: 000114420416087730 The citation records this snapshot. The page link may show a newer release later.	−USD 25.3 million Exact value Exact value: -25296000 USD 2013-01-01 – 2013-12-31: -25296000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2013-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -25296000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25296000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420416087730/rprx-20151231.xml#68343 Filing: 000114420416087730 The citation records this snapshot. The page link may show a newer release later.	USD 63,000 Exact value Exact value: 63000 USD 2013-01-01 – 2013-12-31: 63000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2013-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 63000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 63000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420416087730/rprx-20151231.xml#68541 Filing: 000114420416087730 The citation records this snapshot. The page link may show a newer release later.	−USD 25.36 million Calculation and evidence -25296000 − 63000 USD Exact free cash flow: -25359000 USD 2013-01-01 – 2013-12-31: -25296000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 63000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2013-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -25359000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25296000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420416087730/rprx-20151231.xml#68343 Filing: 000114420416087730 Input fundies:CapitalExpenditure: 63000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420416087730/rprx-20151231.xml#68541 Filing: 000114420416087730 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 32.54 million Exact value Exact value: -32535000 USD 2014-01-01 – 2014-12-31: -32535000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2014-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -32535000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32535000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#70604 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	−USD 29.33 million Exact value Exact value: -29334000 USD 2014-01-01 – 2014-12-31: -29334000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2014-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -29334000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29334000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#76258 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2014-01-01 – 2014-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2014-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#76456 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	−USD 29.33 million Calculation and evidence -29334000 − 0 USD Exact free cash flow: -29334000 USD 2014-01-01 – 2014-12-31: -29334000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2014-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -29334000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29334000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#76258 Filing: 000114420417017919 Input fundies:CapitalExpenditure: 0 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#76456 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 29.19 million Exact value Exact value: -29192000 USD 2015-01-01 – 2015-12-31: -29192000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2015-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -29192000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29192000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#68532 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	−USD 25.33 million Exact value Exact value: -25329000 USD 2015-01-01 – 2015-12-31: -25329000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2015-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -25329000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25329000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73031 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2015-01-01 – 2015-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2015-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73427 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	−USD 25.33 million Calculation and evidence -25329000 − 0 USD Exact free cash flow: -25329000 USD 2015-01-01 – 2015-12-31: -25329000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2015-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -25329000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -25329000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73031 Filing: 000114420417017919 Input fundies:CapitalExpenditure: 0 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73427 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 17.27 million Exact value Exact value: -17273000 USD 2016-01-01 – 2016-12-31: -17273000 USD Inspect Net Income Open source Share or cite Citation for Net Income · REPROS THERAPEUTICS INC. · 2016-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Net Income: -17273000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17273000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#68672 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	−USD 15.58 million Exact value Exact value: -15581000 USD 2016-01-01 – 2016-12-31: -15581000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · REPROS THERAPEUTICS INC. · 2016-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Operating Cash Flow: -15581000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15581000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73229 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2016-01-01 – 2016-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · REPROS THERAPEUTICS INC. · 2016-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73617 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.	−USD 15.58 million Calculation and evidence -15581000 − 0 USD Exact free cash flow: -15581000 USD 2016-01-01 – 2016-12-31: -15581000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · REPROS THERAPEUTICS INC. · 2016-12-31 REPROS THERAPEUTICS INC. (edgar:897075) Free cash flow: -15581000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/897075?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15581000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73229 Filing: 000114420417017919 Input fundies:CapitalExpenditure: 0 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/897075/000114420417017919/rprx-20161231.xml#73617 Filing: 000114420417017919 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

126 filings · 1,962 latest values · 1,962 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000897075, 897075, RPRX, edgar:897075, rprx

Also known as REPROS THERAPEUTICS INC, REPROS THERAPEUTICS INC., ZONAGEN INC

REPROS THERAPEUTICS INC.

Latest quarter

Revenue

Net margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2016 2016-01-01 – 2016-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation